A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer

Cancer type: Colorectal cancer

Phase: I/II

Principal Investigator: Guren Tormod

Country: NO

Keywords: Norway, Oslo, Metastatic colorectal cancer, BRAF mutant

Status: Inclusion completed

Link to